中国实用内科杂志2014，Vol.34Issue(6)：553-557,5.DOI:10.7504/nk2014050102
预防肝移植患者慢性乙型肝炎复发抗病毒治疗现状及进展
Progress in antiviral therapy to prevent HBV recurrence in patients of post-liver transplantation
喻一奇 1张文宏1
作者信息
- 1. 复旦大学附属华山医院,上海 200040
- 折叠
摘要
Abstract
HBV-related end-stage liver disease and hepatocellular carcinoma (HCC) are the major indications for liver transplantation in China.With the introduction of hepatitis B immunoglobulin (HBIG) and oral nucleos (t) ide analogues (NAs),new antiviral therapy has significantly improved the prognosis of liver transplantation.Pre-transplant antiviral therapy will significantly reduce the recurrence rates of HBV infection.All HBsAg-positive patients awaiting liver transplantation for HBV-related end-stage liver disease or HCC should be administered with a potent NA with high barrier to drug resistance to achieve the viral load as low as possible.Additional HBIG administration during the anhepatic phase will achieve a better control of HBV infection.HBIG should be used in combination with NAs post-transplantation to prevent HBV recurrence.As the fact that liver transplant recipients usually need life-long medication to prevent HBV recurrence,it is currently recommended that HBIG can be discontinued in patients under long-term administration of potent NAs with high barrier to drug resistance in combination with HBIG.关键词
乙型肝炎病毒/肝移植/抗病毒治疗/乙型肝炎免疫球蛋白/核苷酸(类)似物Key words
hepatitis B virus / liver transplantation/ anti-viral therapy/ hepatitis B immunoglobulin / nucleos (t) ide analogues分类
医药卫生引用本文复制引用
喻一奇,张文宏..预防肝移植患者慢性乙型肝炎复发抗病毒治疗现状及进展[J].中国实用内科杂志,2014,34(6):553-557,5.
